A Methylene Group on C-2 of 24,24-Difluoro-19-nor-1α,25-dihydroxyvitamin D3 Markedly Increases Bone Calcium Mobilization in Vivo.

Four side chain fluorinated analogues of 1α,25-dihydroxy-19-norvitamin D have been prepared in convergent syntheses using the Wittig-Horner reaction as a key step. Structures and absolute configurations of analogues 3 and 5 were confirmed by X-ray crystallography. All analogues showed high potency in HL-60 cell differentiation and vitamin D-24-hydroxylase (24-OHase) transcription as compared to 1α,25-dihydroxyvitamin D3 (1). Most important is that all of the 20S-configured derivatives (4 and 6) had high bone mobilizing activity in vivo. However, in the 20R series, a 2-methylene group was required for high bone mobilizing activity. A change in positioning of the 20R molecule in the vitamin D receptor when the 2-methylene group is present may provide new insight into the molecular basis of bone calcium mobilization induced by vitamin D.

[1]  H. DeLuca,et al.  A 20S combined with a 22R configuration markedly increases both in vivo and in vitro biological activity of 1α,25-dihydroxy-22-methyl-2-methylene-19-norvitamin D3. , 2012, Journal of medicinal chemistry.

[2]  H. DeLuca,et al.  The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: Results of a 1‐year phase 2 double‐blind, placebo‐controlled, randomized clinical trial , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  T. Harayama,et al.  Synthesis and Biological Activity of Fluorinated Vitamin D , 2010 .

[4]  I. Ojima.  Fluorine in medicinal chemistry and chemical biology , 2009 .

[5]  H. DeLuca,et al.  Synthesis and biological properties of 2-methylene-19-nor-25-dehydro-1alpha-hydroxyvitamin D(3)-26,23-lactones--weak agonists. , 2008, Bioorganic & medicinal chemistry.

[6]  John H. White,et al.  Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist , 2008, Proceedings of the National Academy of Sciences.

[7]  T. Kensler,et al.  Low-calcemic, highly antiproliferative, 1-difluoromethyl hybrid analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: design, synthesis, and preliminary biological evaluation. , 2006, Journal of medicinal chemistry.

[8]  H. DeLuca,et al.  New 2-alkylidene 1alpha,25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxypropylidene) derivatives. , 2006, Journal of medicinal chemistry.

[9]  H. -. Kim,et al.  Highly antiproliferative, low-calcemic, side-chain ketone analogs of the hormone 1alpha,25-dihydroxyvitamin D3. , 2005, Bioorganic & medicinal chemistry.

[10]  H. DeLuca.  Overview of general physiologic features and functions of vitamin D. , 2004, The American journal of clinical nutrition.

[11]  W. R. Dolbier,et al.  The Reformatsky Reaction in Organic Synthesis. Recent Advances , 2004 .

[12]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[13]  G. Posner.  Low-calcemic vitamin D analogs (deltanoids) for human cancer prevention. , 2002, The Journal of nutrition.

[14]  Alessandro Pedretti,et al.  VEGA: a versatile program to convert, handle and visualize molecular structure on Windows-based PCs. , 2002, Journal of molecular graphics & modelling.

[15]  Alex J. Brown,et al.  2,2-Disubstituted analogues of the natural hormone 1α,25-dihydroxyvitamin D3: Chemistry and biology , 2002 .

[16]  T. Noguchi,et al.  Synthesis and biological evaluations of C-23-modified 26,26,26,27,27,27-F6-vitamin D3 analogues. , 2000, Bioorganic & medicinal chemistry.

[17]  S. Gange,et al.  Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis. , 2000, Carcinogenesis.

[18]  G. Han,et al.  Conceptually new sulfone analogues of the hormone 1alpha, 25-dihydroxyvitamin D(3): synthesis and preliminary biological evaluation. , 1999, Journal of medicinal chemistry.

[19]  H. Iwasaki,et al.  Stereoselective Synthesis and Structural Establishment of (25S)-24,24-Difluoro-1α,25,26-trihydroxyvitamin D3, a Major Metabolite of 24,24-Difluoro-1α,25-dihydroxyvitamin D3. , 1999 .

[20]  Keiko Yamamoto,et al.  Stereoselective synthesis and structural establishment of (25S)-24,24-difluoro-1α,25,26-trihydroxyvitamin D3, a major metabolite of 24,24-difluoro-1α,25-dihydroxyvitamin D3 , 1998 .

[21]  H. DeLuca,et al.  New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. , 1998, Journal of medicinal chemistry.

[22]  H. DeLuca,et al.  Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.

[23]  T. Kensler,et al.  Noncalcemic, antiproliferative, transcriptionally active, 24-fluorinated hybrid analogues of the hormone 1alpha, 25-dihydroxyvitamin D3. Synthesis and preliminary biological evaluation. , 1998, Journal of medicinal chemistry.

[24]  Keiko Yamamoto,et al.  1α,25-Dihydroxyvitamin D3-24-Hydroxylase (CYP24) Hydroxylates the Carbon at the End of the Side Chain (C-26) of the C-24-fluorinated Analog of 1α,25-Dihydroxyvitamin D3 * , 1997, The Journal of Biological Chemistry.

[25]  H. DeLuca,et al.  Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. , 1996, Biochemistry.

[26]  G. Molander,et al.  Sequencing Reactions with Samarium(II) Iodide. , 1996, Chemical reviews.

[27]  R. Bouillon,et al.  Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.

[28]  M. Noshiro,et al.  Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. A study with the mature enzyme expressed in Escherichia coli. , 1994, European journal of biochemistry.

[29]  H. DeLuca,et al.  Stabilization of the vitamin D receptor in rat osteosarcoma cells through the action of 1,25-dihydroxyvitamin D3. , 1993, Molecular endocrinology.

[30]  D. Barton,et al.  The invention of radical reactions. Part XXIX. Radical mono- and dideoxygenations with silanes ☆ , 1993 .

[31]  K. Konno,et al.  An Alternative and Efficient Synthesis of 24,24-Difluoro-1α,25- dihydroxyvitamin D3. , 1992 .

[32]  K. Konno,et al.  An Alternative and Efficient Synthesis of 24, 24-Difluoro-1α, 25-dihydroxyvitamin D3 , 1992 .

[33]  G. Molander.  Application of lanthanide reagents in organic synthesis , 1992 .

[34]  H. DeLuca,et al.  Biological activity of fluorinated vitamin D analogs at C-26 and C-27 on human promyelocytic leukemia cells, HL-60. , 1987, Archives of Biochemistry and Biophysics.

[35]  H. DeLuca,et al.  Evidence that 1,25-dihydroxyvitamin D3 is the physiologically active metabolite of vitamin D3. , 1985, Endocrine reviews.

[36]  H. DeLuca,et al.  26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3: a highly potent, long-lasting analog of 1,25-dihydroxyvitamin D3. , 1984, Archives of biochemistry and biophysics.

[37]  H. Flack,et al.  On enantiomorph‐polarity estimation , 1983 .

[38]  S. Mitsuhashi,et al.  Studies on Organic Fluorine Compounds. XXXIX. Studies on Steroids. LXXIX. Synthesis of 1α, 25-Dihydroxy-26, 26, 26, 27, 27, 27-hexafluorovitamin D3 , 1982 .

[39]  B. Lythgoe,et al.  Direct total synthesis of vitamins D2 and D3 , 1977 .

[40]  H. DeLuca,et al.  A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Fried,et al.  2,2-Difluoro-3-hydroxyesters by reformatskii reaction , 1984 .

[42]  M. Ohmori,et al.  Synthesis of 24,24-difluoro-25-hydroxyvitamin D3 , 1979 .

[43]  P. W. Wright,et al.  Calciferol and its relatives. Part 22. A direct total synthesis of vitamin D2 and vitamin D3 , 1978 .

[44]  S. Ruston,et al.  Allylic phosphine oxides as precursors of dienes of defined geometry: Synthesis of 3-deoxyvitamin D2 , 1975 .